Middle East & Africa Opioids Market Forecast to 2030 - Regional Analysis - by Product, Application, Route of Administration, and Distribution Channel

List of Tables

The Middle East & Africa opioids market was valued at US$ 249.22 million in 2022 and is expected to reach US$ 299.79 million by 2030; it is estimated to register a CAGR of 2.3% from 2022 to 2030.

Surging Chronic Pain Incidence Bolster Middle East & Africa Opioids Market

Chronic diseases such as cardiovascular disease, cancer, musculoskeletal diseases, and neurovascular diseases critically affect a person's health by lowering immunity. Moreover, many patients suffering from these conditions experiences chronic pain. The diseases mentioned above are most common in adults and the geriatric population. Nevertheless, cases of these diseases are noticeably growing among children as well. Chronic pain is also common among sportspersons, athletes, and individuals living with past injuries. According to a study published in the NCBI (i.e., National Center for Biotechnology Information), 20% of adults suffer from pain worldwide, and 10% are newly diagnosed with chronic pain per year. While pain affects all populations, regardless of sex, race/ethnicity, income, age, or geography, it is not distributed equally across the world. Prescription opioids, including hydrocodone, oxycodone, and morphine, are potent pain-reducing medications that are used to treat pain caused by injuries, surgeries, and health conditions such as cancer and arthritis.

According to the Congressional Research Service, Americans may get more opioids at the expense of more comprehensive pain therapies. Increased opioid prescribing practices can be attributed to the insurance reimbursement programs that incentivize opioids over alternative pain treatments, cost structures that encourage more efficient care, and evaluations that combine patient satisfaction with effective pain management. Therefore, owing to the advantage of opioids in pain management, the demand is rising among patients with chronic diseases.

Middle East & Africa Opioids Market Overview

The opioids market in the Middle East & Africa is segmented into South Africa, the UAE, Saudi Arabia, and the Rest of Middle East & Africa. In the Middle East & Africa, opioids are used for pain relief, palliative care, and de-addiction of opioids. The standard of care for opioid use disorder involves treatment using medications such as methadone, buprenorphine, or naltrexone; these medications for opioid use disorder (MOUD) reduce opioid overdose deaths. In 2020, MOUD was only available as a treatment modality for opioid use disorder in Lebanon, Morocco, Iran, and the Palestinian Territories. Despite increasing economic and healthcare development in a few countries of the region, there has been a limited increase in opioid consumption in the Middle East & Africa.

Middle East & Africa Opioids Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Opioids Market Segmentation

The Middle East & Africa opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the Middle East & Africa opioids market is segmented immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the Middle East & Africa opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the Middle East & Africa opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the Middle East & Africa opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the Middle East & Africa opioids market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa opioids market share in 2022.

Neuraxpharm Pharmaceuticals SL, Endo International plc, Hikma Pharmaceuticals Plc, Mallinckrodt Plc, Rusan Pharma Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa opioids market.

Product Code: BMIRE00031007

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Opioids Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Surging Chronic Pain Incidence
- 4.1.2 Increasing Geriatric Population
4.2 Market Restraints
- 4.2.1 Increasing Drug Abuse
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Market Players
4.4 Impact of Drivers and Restraints:

5. Opioids Market - Middle East & Africa Analysis

5.1 Middle East & Africa Opioids Market Overview
5.2 Middle East & Africa Opioids Market Revenue (US$ Million), 2020-2030
5.3 Middle East & Africa Opioids Market Forecast Analysis

6. Middle East & Africa Opioids Market Analysis - by Product

6.1 Immediate Release Short Acting Opioid
- 6.1.1 Overview
- 6.1.2 Immediate Release Short Acting Opioid: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.1.2.1 Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
6.2 Extended Release Long-Acting Opioid
- 6.2.1 Overview
- 6.2.2 Extended Release Long-Acting Opioid: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.2.2.1 Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. Middle East & Africa Opioids Market Analysis - by Application

7.1 Pain Management
- 7.1.1 Overview
- 7.1.2 Pain Management: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Anesthesia
- 7.2.1 Overview
- 7.2.2 Anesthesia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Diarrhea Suppression
- 7.3.1 Overview
- 7.3.2 Diarrhea Suppression: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Cough Suppression
- 7.4.1 Overview
- 7.4.2 Cough Suppression: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.5 De-Addiction
- 7.5.1 Overview
- 7.5.2 De-Addiction: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Opioids Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Injectable
- 8.2.1 Overview
- 8.2.2 Injectable: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Transdermal Patch
- 8.3.1 Overview
- 8.3.2 Transdermal Patch: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Opioids Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Middle East & Africa Opioids Market - Country Analysis

10.1 Middle East & Africa
- 10.1.1 Middle East & Africa: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 10.1.1.1 Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.2 Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Product
    - 10.1.1.2.2 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.2.3 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 10.1.1.2.4 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Application
    - 10.1.1.2.5 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Route Of Administration
    - 10.1.1.2.6 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.3 South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 South Africa: Middle East & Africa Opioids Market Breakdown, by Product
    - 10.1.1.3.2 South Africa: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.3.3 South Africa: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 10.1.1.3.4 South Africa: Middle East & Africa Opioids Market Breakdown, by Application
    - 10.1.1.3.5 South Africa: Middle East & Africa Opioids Market Breakdown, by Route Of Administration
    - 10.1.1.3.6 South Africa: Middle East & Africa Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.4 United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.4.1 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Product
    - 10.1.1.4.2 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.4.3 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 10.1.1.4.4 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Application
    - 10.1.1.4.5 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Route Of Administration
    - 10.1.1.4.6 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Distribution Channel
  - 10.1.1.5 Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Product
    - 10.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid
    - 10.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid
    - 10.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Application
    - 10.1.1.5.5 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Route Of Administration
    - 10.1.1.5.6 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Opioids Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Endo International plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Mallinckrodt Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Neuraxpharm Pharmaceuticals SL
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Hikma Pharmaceuticals Plc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Rusan Pharma Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Teva Pharmaceutical Industries Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms